Oncology

Immune checkpoint inhibitors (ICI) use can lead to an array of immune-related adverse events (irAE). Nephritis is considered to be…

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) Congress 2024…

Next-generation sequencing techniques enable rapid detection of mutations present in a patient’s tumour. The next step is to define…

Most female carriers of germline BRCA1 mutations develop breast and/or ovarian cancer. However, the penetrance of BRCA1 pathogenic variants…

Lung cancer (LC) remains the top cause of cancer-associated mortality worldwide, with a 10-year overall survival rate of only 5%.1…

Targeted therapy and immunotherapy have revolutionised the treatment of metastatic non-small cell lung cancer, particularly adenocarcinoma…

FOR the first time, there is an alternative to chemotherapy for patients with advanced or metastatic urothelial carcinoma. The results of a…

Patients with colorectal cancer (CRC) have limited systemic treatment options compared to other major cancer types.1 Tumour heterogeneity is a major cause of treatment failure.